Firebrick Pharma Ltd (ASX: FRE) Share Price and News

Dr Molloy at Pharmacia was Managing Director of Australia/NZ operations and later Vice President for Strategic Marketing, responsible for the marketing of hundreds of pharmaceuticals across 22 countries. During his pharmaceutical career, he has directly launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals. He was responsible for the creation and launch in Australia of Betadine Sore Throat Gargle, which subsequently became a leading OTC product in Australia and the inspiration for the development of Nasodine. He is a founder of Firebrick and co inventor on all the key Firebrick patents.

Dr Goodall has a successful track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was Chief Operating Officer of Viralytics, which was later successfully acquired in 2018 for $500 million by the US big pharma company, Merck. Previously, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical for 11 years. He has experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has a background in process development, production scale up and GMP manufacturing for pharmaceuticals. He is a founder of Firebrick and co inventor on all the key Firebrick patents.

Mr Legleiter has worked in both the public and private sectors within senior executive and leadership roles for both start-up and global healthcare corporations in Australia, the USA, Germany and China. Recently, he held the position of Chief Executive Officer at Adherium Limited (ASX:ADR), an international digital health remote patient monitoring and clinical trials business.

-

-